ArticleJMA journal2025
Cross-sectional Survey of Hypertension Management among Patients Stratified by Chronic Kidney Disease in Japan.
Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite progress in hypertension management, blood pressure (BP) control remains insufficient, and this so-called hypertension paradox is an urgent issue. Following the 2019 revision of the Guidelines for Hypertension Management, we reported that patients requiring stringent BP regulation highlight the unachieved goals of hypertension management. BP management is a basic and validated strategy for patients with chronic kidney disease (CKD) but its achievement rate has been under-reported. Methods: We collected and compared cross-sectional data of patients with hypertension in Kanagawa, Japan for 2011 and 2014 by accessing the Japan Medical Association Database of Clinical Medicine. Results: Patients with and without CKD were included as follows: 316/488 in 2011, 152/946 in 2014, and 396/385 in 2021, respectively. In the 2021 study, the target office BP (130/80 mmHg) and home BP (<125/75 mmHg) were achieved in 36.3% and 57.9% of patients with CKD, respectively, and this was a significant improvement over the results reported in the 2014 study (p < 0.05). In contrast, the 2021 study on patients without CKD had a significantly lower achievement rate for a stringent BP target compared to the 2014 study (p < 0.05), especially for patients without diabetes (p = 0.004). Unlike trends in patients without CKD, home BP control in patients with hypertension and CKD has improved over the past decade. Conclusions: The stringent BP target achievement rate remains insufficient in patients with CKD, indicating that CKD campaigns or resolution of clinical inertia resulting from an insufficient number of concomitant drugs is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.